Treatment alternatives for Mycobacterium kansasii

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 4, 2001, Pages 417-420

  Graybill, John R ^a,b   Bocanegra, Rosie ^a  

^a University of Texas Health Science Center   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; ETHAMBUTOL; ISONIAZID; PROTEINASE; RIFAMPICIN; RIFAPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFICACY; INTERMETHOD COMPARISON; MONOTHERAPY; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM KANSASII; NONHUMAN; NUDE MOUSE;

EID: 0035049650     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.4.417     Document Type: Article

References (9)

1. Species distribution in human immunodeficiency virus-related mycrobacterial infections: Implications for selection of initial treatment
2. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS)
3. Mycobacterium kansasii bacteremia in patients infected with human immunodeficiency virus
4. In vitro susceptibility of Mycobacterium kansasii to clarithromycin
5. Rifampin-resistant Myobacterium kansasii
6. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages
7. Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid
8. Activities of azithromycin and clarithromycin against nontuberculous mycobacteria in beige mice
9. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system